Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00327626
(study was never started due to regional geopolitical conflict)
The aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of two ISIS 113715 subcutaneous doses (15 mg and 30 mg/day) in combination with oral antidiabetic agents (OAD) versus OAD + placebo in patients with inadequately controlled type 2 diabetes, despite ongoing maximal treatment with OAD.
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of ISIS 113715 Administered Daily in Patients With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
Study Start Date
Estimated Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female (post-menopausal and/or surgically sterile)
Aged 18 to 70 years
Diagnosed with type 2 diabetes mellitus of eight years or less in duration
Being treated with OAD at stable maximum doses [defined as at least 10 mg/day glibenclamide (preferred), or 20 mg/day glipizide, with or without at least 1,500 mg/day metformin] for at least three months prior to screening
Having fasting plasma glucose levels of 150-270 mg/dL and HbA1c levels of 7.5-11.0%
Greater than 3 severe hypoglycemic episodes within six months of screen
Pregnant, breastfeeding, or intends to become pregnant
Clinical signs or symptoms of liver disease, acute, or chronic hepatitis, or ALT greater than the upper limit of normal
Positive hepatitis B surface antigen, hepatitis C antibody, or HIV test
Patients with history of renal transplantation or renal dialysis or microalbuminuria defined as urine albumin > 200 mg/day
History of insulin use within three months of screen
History of diabetic ketoacidosis
Treatment with any thiazolidinedione (e.g., rosiglitazone) within three months of screen
History of lactic acidosis while on metformin therapy
Complications of diabetes (e.g., neuropathy, nephropathy, and retinopathy)
Clinically significant and currently active diseases
Clinical significant abnormalities in medical history, physical examination, or laboratory examination